Pharmaceuticals, Biotechnology and Life Sciences
The FDA approved an expanded indication of ViiV Healthcare’s Dovato (dolutegravir/lamivudine), a complete two-drug regimen for virologically suppressed adults with HIV-1 with no history of treatment failure or resistance to Dovato’s components.
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, this week said that the European Commission has granted Marketing Authorisation for HIV-1 infection treatment, Dovato.
The U.S. Food and Drug Administration Monday approved Dovato, two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.